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OBJECTIVES To evaluate whether use of beta-adrenergic blocking agents, alone or in combination with
specific antiarrhythmic therapy, is associated with improved survival in persons with
ventricular fibrillation (VF) or symptomatic ventricular tachycardia (VT).
BACKGROUND The ability of beta-blockers to alter the mortality of patients with VF or VT receiving
contemporary medical management is not well defined.
METHODS Survival of 1,016 randomized and 2,101 eligible, nonrandomized patients with VF or
symptomatic VT followed in the Antiarrhythmics Versus Implantable Defibrillators (AVID)
trial through December 31, 1996 was assessed using Cox proportional hazards analysis.
RESULTS The 817 (28%) patients discharged from hospital receiving beta-blockers had less ventricular
dysfunction, fewer symptoms of heart failure and a different pattern of medication use
compared with patients not receiving beta-blockers. Before adjustment for important
prognostic variables, beta-blockade was not significantly associated with survival in random-
ized or in eligible, nonrandomized patients treated with specific antiarrhythmic therapy. After
adjustment, beta-blockade remained unrelated to survival in randomized or in eligible,
nonrandomized patients treated with amiodarone alone (n 5 1142; adjusted relative risk [RR]
5 0.96; 95% confidence interval [CI] 0.64–1.45; p 5 0.85) or a defibrillator alone (n 5 1347;
adjusted RR 5 0.88; 95% CI 0.55 to 1.40; p 5 0.58). In contrast, beta-blockade was
independently associated with improved survival in eligible, nonrandomized patients who
were not treated with specific antiarrhythmic therapy (n 5 412; adjusted RR 5 0.47; 95% CI
0.25 to 0.88; p 5 0.018).
CONCLUSIONS Beta-blocker use was independently associated with improved survival in patients with VF or
symptomatic VT who were not treated with specific antiarrhythmic therapy, but a protective
effect was not prominent in patients already receiving amiodarone or a defibrillator. (J Am
Coll Cardiol 1999;34:325–33) © 1999 by the American College of Cardiology
Beta-adrenergic blocking agents have been shown to reduce
the incidence of sudden death and total mortality in patients
with a recent myocardial infarction (MI) (1,2) and in
patients with symptomatic heart failure (3–5). Furthermore,
beta-blockers have been advocated for use in patients with
ventricular fibrillation (VF) and ventricular tachycardia
(VT), in whom these agents appear to reduce the incidence
of recurrent ventricular tachyarrhythmias (6,7). Although
beta-blockade has been associated with a reduced risk of
death for patients with VF and VT (8,9), the ability of these
agents to alter survival in patients receiving contemporary
medical therapy is not known.
Post hoc analyses from two high-risk, post-MI trials have
indicated that patients receiving amiodarone and a beta-
blocker are at a substantially (30% to 72%) lower risk of
death compared with patients treated with amiodarone
alone (10–14). Whether beta-blockers alter the survival of
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patients with VF or VT treated with amiodarone is uncer-
tain. Likewise, the capacity of beta-blockers to alter the
mortality of patients with these arrhythmias, who have
already received an implantable cardioverter defibrillator
(ICD), has not been fully investigated.
The Antiarrhythmics Versus Implantable Defibrillators
(AVID) trial evaluated the mortality difference of antiar-
rhythmic drugs versus ICD therapy in patients with VF or
symptomatic VT. The AVID trial was terminated early due
to improved survival in patients randomized to ICD therapy
(15). Although these results are compelling, the more
frequent use of beta-blockers in ICD-treated patients has
led some authors to question the superiority of ICD therapy
(16).
This analysis evaluated the association of beta-blocker
use, alone and in combination with amiodarone or an ICD,
with survival in AVID patients with VF or symptomatic VT.
METHODS
Definitions. For the purpose of this analysis, symptomatic
VT was defined as VT with syncope or VT with hemody-
namic compromise and a left ventricular (LV) ejection
fraction #0.40. Patients presenting with VF or symptom-
atic VT were eligible for randomization, whereas those
already receiving amiodarone, with ventricular arrhythmias
secondary to a correctable cause, a limited life expectancy,
New York Heart Association (NYHA) class IV symptoms
or contraindications to amiodarone or ICD therapy were
not eligible for randomization (17–19).
Study population (Fig. 1). The AVID registry included
patients enrolled in the randomized trial (15) and patients
screened, but not randomized (17–19). There were 3,117
registry patients with VF or symptomatic VT as their index
arrhythmia, 2,901 (93%) of whom were discharged from
hospital with aminodarone alone, an ICD alone or neither
of these therapies. Survival of the 970 randomized and
1,931 eligible, nonrandomized patients with VF or symp-
tomatic VT who received one of these three treatment
strategies, and thus were included in the present analysis,
was determined using the National Death Index, as of
December 31, 1996.
Beta-blocker use. Beta-blocker use was defined at the time
of hospital discharge. Randomized patients had beta-
blocker use reevaluated quarterly. Information on the spe-
cific agents and doses used were collected for all 284
randomized patients prescribed beta-blockers at any time
during the course of the trial. Reasons for beta-blocker use
were ascertained for all 220 randomized patients who were
first prescribed beta-blockers after their index arrhythmia.
Statistical analysis. Continuous baseline characteristics are
presented as mean 6 SD. Univariate comparisons were
made using analysis of variance or the chi-square test.
Pair-wise comparisons were made using a Student t test
or chi-square test. All-cause mortality was the primary
end point of this analysis. Deaths in randomized patients
were further classified as cardiac or noncardiac (20), and
cause-specific mortality rates were compared using the
log-rank test statistic. The composite end point of death
or recurrent arrhythmia (21,22) was also evaluated in
randomized patients. Stratification by history of MI (23)
and index arrhythmia (23) was performed in the com-
bined groups of amiodarone-treated and ICD-treated
patients. Amiodarone-treated patients were stratified by
heart rate (,70 vs. $70 beats/min) at the time of hospital
discharge (12–14). Cox proportional hazards models were
used to evaluate the univariate (unadjusted) and multivariate
(adjusted) association of beta-blockers with survival. The
prespecified multivariate model included beta-blocker use,
age, gender, race, index arrhythmia, history of heart failure,
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AVID 5 Antiarrhythmics Versus Implantable
Defibrillators
CAMIAT 5 Canadian Amiodarone Myocardial
Infarction Arrhythmia Trial
EMIAT 5 European Myocardial Infarct Amiodarone
Trial
CI 5 confidence interval
ICD 5 implantable cardioverter defibrillator
LV 5 left ventricular
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RR 5 relative risk
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Figure 1. The 2,901 persons in the present analysis included 970
randomized and 1,931 eligible, nonrandomized patients dis-
charged from hospital with amiodarone alone, an ICD alone or
neither of these therapies. Numbers of patients within each
treatment strategy are shown in parentheses.
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ejection fraction, heart rate at hospital discharge and any
relevant baseline differences between patients receiving,
versus those not receiving, beta-blockers. The Cox models
were used to determine relative risk (RR) estimates and 95%
confidence intervals (CI). Analyses were performed using
SIR (Scientific Information Retrieval Inc., New South
Wales, Australia), SPSS 6.1 (SPSS Inc., Chicago, Illinois)
and Stata Release 5.0 (Stata Corporation, College Park,
Texas) statistical software.
RESULTS
Characteristics and beta-blocker use, randomized pa-
tients. Patients discharged receiving beta-blockers had
fewer symptoms of heart failure and were less likely to be
prescribed a diuretic or angiotensin-converting enzyme
(ACE) inhibitor compared with those not receiving beta-
blockers (Table 1). Patients receiving an ICD and beta-
blocker had less LV dysfunction, slower mean heart rates at
hospital discharge and were less likely to be prescribed
digoxin or a calcium channel blocker, but more likely to be
prescribed aspirin compared with those receiving an ICD
alone.
Despite the encouraged use of beta-blockers in all pa-
tients in whom they were clinically indicated, amiodarone-
treated patients were less likely to be discharged receiving a
beta-blocker (16%) compared with ICD-treated patients
(42%; p , 0.001). Similarly, the use of beta-blockers at any
time during follow-up was less frequent in amiodarone-
treated patients (23% vs. 56% in ICD-treated patients; p ,
0.001). Information on beta-blocker use at one year was
available for 62 amiodarone-treated and 186 ICD-treated
patients. At one year, 65% of amiodarone-treated and 81%
of ICD-treated patients discharged receiving a beta-blocker
continued to take these agents.
Reasons for use of beta-blockers, agents and doses,
randomized patients. Beta-blockers were most commonly
prescribed after the index arrhythmia for the ventricular
arrhythmia itself or the presence of coronary artery disease.
A greater proportion of ICD-treated patients received
beta-blockers for supraventricular arrhythmias or sinus
tachycardia, whereas a greater proportion of amiodarone-
treated patients received beta-blockers for hypertension
(Table 2).
Most of the 284 randomized patients receiving beta-
blockers during follow-up were prescribed metoprolol (n 5
180; 63%) or atenolol (n 5 74; 26%). Amiodarone and
Table 1. Characteristics of Randomized Patients, by Use of Beta-blockers
Characteristic
Amiodarone Defibrillator
Beta-
blocker
No Beta-
blocker
Beta-
blocker
No Beta-
blocker
Number 77 407 203 283
Age (yrs) 65 6 11 65 6 10 64 6 11 65 6 11
Male 88% 79% 82% 74%
Non-white race 14% 15% 11% 14%
Moderate-severe left
ventricular dysfunction
63% 73% 58%‡ 76%
Heart rate (beats/min) 66 6 13 69 6 12 73 6 12‡ 79 6 14
Systolic BP (mm Hg) 125 6 19 121 6 17 121 6 18 121 6 18
Ventricular fibrillation 44% 45% 45% 44%
History of
Myocardial infarction 73% 66% 70% 63%
Hypertension 60% 55% 55% 56%
Diabetes 27% 23% 23% 26%
Heart failure 34%* 50% 36%‡ 52%
Medication use
ACE inhibitor 60%* 71% 62%† 73%
Digoxin 32% 44% 37%‡ 53%
Calcium blocker 17% 12% 12%† 22%
Aspirin 62% 58% 68%† 56%
Warfarin 31% 34% 19% 19%
Diuretic 37%† 55% 36%‡ 57%
Sotalol 0% 0% 0% 1%
Other antiarrhythmic 1% 2% 3% 7%
Revascularization
Before index arrhythmia 44% 34% 34% 36%
After index arrhythmia 10% 12% 12% 9%
*p , 0.05; †p , 0.01 or ‡p # 0.001 for beta-blocker vs. no beta-blocker.
ACE 5 angiotensin-converting enzyme; BP 5 blood pressure.
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ICD-treated patients received similar mean doses of meto-
prolol at the time of hospital discharge (68 mg vs. 71 mg per
day, respectively; p 5 0.62), but amiodarone-treated pa-
tients tended to receive lower doses at one year of follow-up
(61 mg vs. 80 mg per day for ICD-treated patients; p 5
0.07). Atenolol was prescribed at similar mean doses at the
time of hospital discharge (40 mg vs. 48 mg daily, respec-
tively; p 5 0.18) and at one year (34 mg vs. 47 mg daily,
respectively; p 5 0.15). The remaining 30 (11%) patients
received propranolol, another nonselective agent or acebu-
tolol.
Characteristics and beta-blocker use, eligible, nonran-
domized patients. Among the three treatment groups,
those receiving amiodarone were older and had slower mean
heart rates at the time of hospital discharge (Table 3).
Amiodarone-treated patients were also less likely to have
had VF as their index arrhythmia, more likely to have a
history of heart failure and more likely to be prescribed
warfarin or a diuretic. The ICD-treated patients were more
often white and less likely to have a history of hypertension,
compared with the other two groups. Otherwise untreated
patients had less LV dysfunction and were less likely to have
a history of MI compared with those treated with amioda-
rone or an ICD. Untreated patients were also less likely to
be prescribed an ACE inhibitor, but more likely to receive
sotalol or another antiarrhythmic drug, and more likely to
have undergone a coronary artery bypass or coronary artery
angioplasty procedure after their index arrhythmia, com-
pared with patients treated with amiodarone or an ICD.
Amiodarone-treated patients were less likely to be pre-
scribed beta-blockers at the time of hospital discharge (16%)
Table 2. Reasons for Beta-blocker Prescription, Randomized
Patients After Their Index Arrhythmia (n 5 220)
Reasons for Beta-
blocker Use*
Amiodarone
(n 5 55)
Defibrillator
(n 5 165)
Ventricular arrhythmia 47% 44%
Coronary artery disease,
prior myocardial
infarction
30% 29%
Coronary artery disease,
angina
14% 16%
Hypertension 22%† 10%
Supraventricular
arrhythmia/sinus
tachycardia
2% 14%†
Frequent defibrillator
shocks
0% 3%
Other reason 9% 4%
*Multiple reasons were provided for 20% of amiodarone and 16% of defibrillator
patients; †p , 0.05.
Table 3. Characteristics of Eligible, Nonrandomized Patients
Characteristic Amiodarone Defibrillator Neither
Number 658 861 412
Age (yrs) 67 6 12* 62 6 13 63 6 12
Male 73% 75% 71%
Non-white race 12% 6%* 10%
Moderate-severe LV dysfunction 73% 65% 54%*
Heart rate (bpm) 71 6 13‡ 75 6 13 77 6 15
Systolic BP (mm Hg) 121 6 19 120 6 18 121 6 19
Ventricular fibrillation 41%‡ 56% 51%
History of
Myocardial infarction 56% 57% 48%*
Hypertension 54% 44%† 53%
Diabetes 24% 18% 20%
Heart failure 51%‡ 40% 33%
Medication use
Beta-blocker 16%‡ 32% 40%‡
ACE inhibitor 61% 57% 47%†
Digoxin 40% 43% 37%
Calcium blocker 12% 14% 16%
Aspirin 51% 56% 58%
Warfarin 30%† 23% 22%
Diuretic 57%‡ 45% 41%
Sotalol 0% 6% 12%†
Other antiarrhythmic 5% 7% 17%‡
Revascularization
Before index arrhythmia 34% 38% 29%
After index arrhythmia 9% 12% 33%‡
*p , 0.05; †p , 0.01 or ‡p # 0.001 for indicated group vs. the other groups.
ACE 5 angiotensin-converting enzyme; LV 5 left ventricular; BP 5 blood pressure.
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than ICD-treated patients (32%), who, in turn, were less
likely to receive these agents compared with otherwise
untreated patients (37%) (Table 3). Information regarding
the beta-blockers used and their doses was not available for
eligible, nonrandomized patients.
Eligible, nonrandomized patients receiving beta-
blockers had less LV dysfunction, were less likely to have
a history of heart failure and were less likely to be
prescribed a diuretic, but more likely to be prescribed
aspirin compared with those not receiving beta-blockers
(Table 4). Patients receiving amiodarone and a beta-
blocker were younger on average, and more often white
compared with those receiving amiodarone alone. Pa-
tients receiving amiodarone and a beta-blocker had
slower mean heart rates, were more likely to have VF or
a history of hypertension but less likely to be prescribed
an ACE inhibitor compared with those receiving amio-
darone alone. Patients receiving an ICD and beta-blocker
had slower mean heart rates and were more likely to have
a history of hypertension, but were less likely to receive
digoxin, warfarin or sotalol compared with those receiv-
ing an ICD alone. Patients receiving an ICD and
beta-blocker were also more likely to have undergone a
revascularization procedure after their index arrhythmia
compared with those receiving an ICD alone. Untreated
patients receiving beta-blockers were more likely to have
VF, but less likely to be prescribed an ACE inhibitor,
digoxin or sotalol compared with patients not receiving
amiodarone, an ICD or beta-blocker. Untreated patients
receiving beta-blockers were also more likely to have
undergone a revascularization procedure after their index
arrhythmia compared with patients not receiving beta-
blockers (Table 4).
Unadjusted (univariate) survival. Beta-blocker use at the
time of hospital discharge was not associated with survival
in randomized amiodarone-treated (RR 5 0.88; 95% CI
0.48 to 1.61; p 5 0.67) or ICD-treated patients (RR 5
0.69; 95% CI 0.39 to 1.24; p 5 0.22). Beta-blockade was
similarly not associated with survival in eligible, nonran-
domized patients treated with amiodarone alone (RR 5
0.67; 95% CI 0.42 to 1.05; p 5 0.08) or an ICD alone
(RR 5 0.59; 95% CI 0.32 to 1.12; p 5 0.10). In contrast,
beta-blockade was associated with significantly improved
survival in patients not treated with amiodarone or an ICD
(RR 5 0.36; 0.21 to 0.64; p 5 0.0004).
Modes of death, randomized patients (Table 5). Most
deaths in randomized patients were classified as cardiac.
Table 4. Characteristics of Eligible, Nonrandomized Patients, by Use of Beta-blockers
Characteristic
Amiodarone Defibrillator Neither
BB No BB BB No BB BB No BB
Number 110 548 255 586 152 260
Age (yrs) 64 6 12* 67 6 12 62 6 12 62 6 13 62 6 12 63 6 12
Male 80% 73% 79% 74% 75% 69%
Non-white race 8%* 17% 6% 9% 10% 14%
Moderate-severe 61%‡ 76% 55%‡ 70% 39%‡ 63%
LV dysfunction
Heart rate (beats/min) 68 6 13* 72 6 13 72 6 13‡ 77 6 13 75 6 14 77 6 15
Systolic BP (mm Hg) 121 6 17 121 6 19 120 6 18 119 6 17 121 6 18 119 6 20
Ventricular fibrillation 53%* 39% 61% 54% 57% 47%
History of
Myocardial infarction 56% 57% 60% 55% 47% 49%
Hypertension 61%* 52% 52%† 41% 60% 47%
Diabetes 17% 25% 18% 18% 18% 22%
Heart failure 30%‡ 55% 28%‡ 45% 20%‡ 42%
Medication use
ACE inhibitor 46%† 61% 53% 58% 40%* 48%
Digoxin 34% 42% 27%‡ 50% 28%† 40%
Calcium blocker 12% 13% 16% 14% 16% 16%
Aspirin 66%* 49% 65%‡ 51% 65%* 50%
Warfarin 27% 30% 16%† 25% 19% 23%
Diuretic 39%‡ 61% 31%‡ 51% 33%‡ 47%
Sotalol 0% 0% 2%‡ 8% 1%‡ 18%
Other antiarrhythmic 3% 6% 6% 8% 16% 19%
Revascularization
Before index arrhythmia 33% 26% 35% 35% 22% 30%
After index arrhythmia 14% 8% 16%* 11% 44%‡ 23%
*p , 0.05; †p , 0.01 or ‡p # 0.001 for beta-blocker vs. no beta-blocker in that group.
ACE 5 angiotensin-converting enzyme; BB 5 beta-blocker; BP 5 blood pressure; LV 5 left ventricular.
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Cardiac death rates were somewhat lower in patients receiv-
ing beta-blockers, while noncardiac death rates were similar
in patients receiving beta-blockers versus those not receiving
beta-blockers.
Adjusted survival, randomized patients. The use of beta-
blockers at the time of hospital discharge was not indepen-
dently associated with survival in randomized patients
(Table 6). Furthermore, the survival of patients receiving
beta-blockers at the time of their index arrhythmia who
continued to receive these agents was similar to that of
patients in whom beta-blockers were initiated after their
index arrhythmia (RR 5 0.81; 95% CI 0.45 to 1.46; p 5
0.49). Patients receiving amiodarone and a beta-blocker, or
an ICD and a beta-blocker, had a survival similar to patients
receiving amiodarone alone, or an ICD alone.
Age (RR 5 1.32 per decade increase), ejection fraction
(RR 5 0.69 per 0.10 increase), history of heart failure
(RR 5 3.06) and ACE inhibitor use (RR 5 0.44) were
significantly associated with survival in the amiodarone-
treatment multivariate model. For ICD-treated patients,
age (RR 5 1.54 per decade), white race (RR 5 0.49), ACE
inhibitor use (RR 5 0.47) and other antiarrhythmic drug
use (RR 5 2.81) were significantly associated with survival
in the multivariate model.
Adjusted survival, eligible, nonrandomized patients.
Overall, beta-blocker use was associated with improved
survival in eligible, nonrandomized patients (Table 6).
However, beta-blockade was not associated with an inde-
pendent, survival benefit in patients treated with amioda-
rone alone or an ICD alone. In contrast, beta-blocker use
remained associated with a significant, independent survival
benefit in otherwise untreated patients. Furthermore, be-
cause 49 (12%) of these 412 otherwise untreated patients
received sotalol (Table 3), the association of beta-blocker
use with survival was evaluated in patients discharged
without amiodarone, an ICD or sotalol. In these 363
patients, beta-blocker use remained independently associ-
ated with improved survival (RR 5 0.46; 95% CI 0.24 to
0.87; p 5 0.012), with a point estimate similar to that
observed for the entire group of 412 patients (Table 6).
For amiodarone-treated patients, age (RR 5 1.66 per
decade increase), ejection fraction (RR 5 0.80 per 0.10
increase), discharge heart rate (RR 5 1.16 per 10 beats/min
increase), history of heart failure (RR 5 1.56) and use of
other antiarrhythmic drugs (RR 5 2.28) were significantly
associated with survival in the multivariate model. For
ICD-treated patients, age (RR 5 1.49 per decade increase),
ejection fraction (RR 5 0.78 per 0.10 increase) and history
of heart failure (RR 5 2.89) were significantly associated
with survival in the multivariate model. In addition to
Table 5. Modes of Death, Randomized Patients
Cardiac Non-Cardiac
Beta-blocker No Beta-blocker Beta-blocker No Beta-blocker
Deaths Rate* Deaths Rate* Deaths Rate* Deaths Rate*
Amiodarone 11.8% 9.1 17.2% 12.7 5.9% 4.6 3.7% 2.7
Defibrillator 5.3% 4.0 10.9% 7.1 3.2% 2.4 3.6% 2.4
*Incidence rate per 100 person-years over the initial 2 years of follow-up.
All log rank p values were .0.1 for all beta-blocker vs. no beta-blocker comparisons.
Table 6. Adjusted Relative Risk Estimates, Association of Beta-blocker Use with Mortality
Group Number
Relative Risk
(95% CI)*
p
Value
Randomized patients 970 0.84 (0.53–1.28) 0.38
Amiodarone 484 1.00 (0.52–1.91) 0.99
Defibrillator 486 0.75 (0.39–1.46)† 0.40
Nonrandomized patients 1,931 0.67 (0.47–0.94) 0.020
Amiodarone 658 0.98 (0.58–1.66)‡ 0.94
Defibrillator 861 0.88 (0.43–1.78)§ 0.71
Neither 412 0.47 (0.25–0.88)¶ 0.018
Randomized and nonrandomized
Amiodarone 1,142 0.96 (0.64–1.45) 0.85
Defibrillator 1,347 0.88 (0.55–1.40) 0.58
*All Cox models included beta-blocker use at hospital discharge, age, gender, race, index arrhythmia, history of heart failure,
ejection fraction, discharge heart rate and the baseline use of an angiotensin-converting enzyme inhibitor or diuretic.
Specified models also included baseline: †digoxin, calcium channel blocker or aspirin use; ‡aspirin use; §digoxin, aspirin,
warfarin or sotalol use, history of hypertension and revascularization after the index event; ¶digoxin, aspirin or sotalol use, and
revascularization after the index event.
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beta-blockade, age (RR 5 1.48 per decade increase) was
significantly associated with survival in the otherwise un-
treated patient multivariate model.
Death or recurrent arrhythmia, randomized patients.
Beta-blockade was not associated with a reduction in the
composite end point of death or recurrent arrhythmia in
amiodarone and ICD-treated patients separately, or com-
bined (adjusted RR 5 0.97, 95% CI 0.73 to 1.30, p 5 0.86).
Discharge heart rate, amiodarone-treated patients. In
the combined group of 1,142 amiodarone-treated patients, a
heart rate $70 beats/min at the time of hospital discharge
was associated with an increased risk of death compared
with a heart rate of ,70 beats/min (adjusted RR 5 1.30;
95% CI 1.00 to 1.69; p 5 0.047). However, no significant
association between survival and beta-blockade was ob-
served in patients within either heart rate strata (p . 0.4 for
each).
Influence of index arrhythmia and MI history. In the
combined group of 1,142 amiodarone-treated patients,
beta-blockade was not associated with survival in the 655
(57%) patients with symptomatic VT (RR 5 0.81; 95% CI
0.47 to 1.41; p 5 0.45) or the 487 (43%) patients with VF
(RR 5 1.14; 95% CI 0.61–2.16; p 5 0.67). Similarly, in the
combined group of 1,347 ICD-treated patients, beta-
blockade was not associated with survival in the 649 (48%)
patients with symptomatic VT (RR 5 0.69; 95% CI 0.33 to
1.43; p 5 0.30) or the 698 (52%) with VF (RR 5 1.03; 95%
CI 0.54 to 2.00; p 5 0.91).
In the combined group of amiodarone-treated patients,
beta-blocker use was not associated with improved survival
in the 450 (39%) patients with no history of MI (RR 5
0.80; 95% CI 0.41 to 1.59; p 5 0.52) or the 692 (61%) with
a history of prior MI (RR 5 1.07; 95% CI 0.64 to 1.82; p 5
0.78). However, in the combined group of ICD-treated
patients, beta-blocker use was associated with a trend
toward improved survival in the 529 (39%) patients without
a history of MI (RR 5 0.43; 95% CI 0.16 to 1.17; p 5
0.08). Beta-blocker use was not significantly associated with
survival in the combined group of 818 (61%) ICD-treated
patients with a history of MI (RR 5 0.99; 95% CI 0.55 to
1.76; p 5 0.97).
DISCUSSION
The present analysis demonstrates that beta-blocker use at
the time of hospital discharge was not associated with
improved survival in patients with VF or symptomatic VT
treated with amiodarone alone or an ICD alone. However,
beta-blocker use was associated with an independent mor-
tality reduction in eligible, nonrandomized patients who
were not treated with amiodarone or ICD therapy.
Amiodarone-treated patients. Amiodarone has a variety
of electrophysiologic effects, including a weak nonselective,
noncompetitive beta-blocking property (24). Because ami-
odarone and beta-blockers may exert their antiarrhythmic
effects by reducing sympathetic tone (25,26), their combi-
nation might be expected to be superior to the effect of
either alone. Whereas combining these agents is often
avoided because of concern over side effects, excess rates of
adverse cardiovascular and noncardiovascular effects have
not been observed compared with therapy with a beta-
blocker alone (27) or amiodarone alone (10,11).
The European Myocardial Infarct Amiodarone Trial
(EMIAT) and Canadian Amiodarone Myocardial Infarc-
tion Arrhythmia Trial (CAMIAT) were randomized,
placebo-controlled studies that evaluated the capacity of
amiodarone to reduce overall mortality and arrhythmic
death in high-risk post-MI patients, respectively (10,11).
Whereas neither study found a significant reduction in
overall mortality, post hoc analyses from both trials indi-
cated that patients receiving amiodarone and a beta-blocker
had a lower risk of death compared with patients receiving
amiodarone alone (12–14). In EMIAT and CAMIAT,
unadjusted all-cause mortality reductions of 30% (12) and
60% to 72% (14), respectively, were observed. Furthermore,
in both analyses, the beneficial effect of combining amioda-
rone with a beta-blocker was most prominent in patients
with more rapid baseline heart rates. In contrast with
EMIAT and CAMIAT, the combination of amiodarone
and a beta-blocker in AVID patients was not associated
with improved survival. This result may reflect differences
between the amiodarone-treated patients in AVID versus
those in EMIAT and CAMIAT. Although the age and
gender distribution of patients in the three trials was similar,
patients in AVID had life-threatening ventricular arrhyth-
mias, more advanced LV dysfunction and a greater use of
heart failure medications. Finally, although the analyses
from EMIAT and CAMIAT demonstrated that patients
with more rapid heart rates had the greatest benefit from the
combination of amiodarone and a beta-blocker (12–14), the
present analysis did not corroborate this. However,
amiodarone-treated patients in AVID with heart rates
$70 beats/min were at a higher risk of death. This result
may reflect differences in the timing of the baseline heart
rate measurements in AVID (at hospital discharge) versus
EMIAT and CAMIAT (before initiation of amiodarone)
or differences in the study populations.
Patients treated with an implantable cardioverter defi-
brillator. Because beta-blockers reduce mortality in per-
sons with heart failure (3–5), they would be expected to be
beneficial in ICD-treated patients, most of whom have LV
dysfunction. Furthermore, although beta-blockers may be
used in conjunction with ICD therapy to reduce the
incidence of recurrent arrhythmias (21,22), this was not a
common reason cited for the use of beta-blockers in
randomized AVID patients. Furthermore, beta-blockade
was not associated with a significant reduction in the
composite end point of death or recurrent arrhythmia in
randomized AVID patients.
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Beta-blockers have been shown to reduce mortality when
initiated in the early phase of an acute MI, particularly in
patients with LV dysfunction (1,2), yet the ability of
beta-blockers to reduce mortality when administered be-
yond the immediate post-MI period appears less certain
(28,29). However, recent randomized trials in patients with
heart failure which have included persons with ischemic
heart disease have demonstrated significant mortality reduc-
tions in patients treated with beta-blockers, mostly the
result of a reduced risk of sudden death (4,5).
Otherwise untreated patients. In the same clinical prac-
tice setting, patients with VF or symptomatic VT who
receive amiodarone or ICD therapy are likely to differ from
patients who are otherwise untreated. In the present anal-
ysis, these otherwise untreated patients had less LV dys-
function, fewer symptoms of heart failure and less frequent
ACE inhibitor or diuretic use compared with eligible,
nonrandomized patients treated with amiodarone or an
ICD.
Because beta-blockers appear to decrease mortality by
reducing the incidence of sudden death in patients with
ischemic heart disease (30) and heart failure (4,5), it is
probable that the survival benefit observed with beta-
blockade in the otherwise untreated AVID patients was due
to a decline in sudden death. Because amiodarone and ICD
therapy are primarily used to reduce sudden, arrhythmic
death in patients with VF or VT, it is not surprising that
beta-blocker use was not associated with a prominent,
additive survival benefit in AVID. Finally, the rate of
revascularization after the index arrhythmia was also great-
est in the otherwise untreated patients. This discrepancy
may also have been an important factor in the results
observed (31). However, the results of the present analysis
are consistent with previous work by Brodsky and col-
leagues, who reported that concomitant beta-blockade was
most efficacious in VT/VF patients who were younger, had
less LV dysfunction and no history of coronary artery
disease (23).
Study limitations. This analysis was not a randomized
comparison of outcome in patients receiving, versus those
not receiving, beta-blockers. Although adjustments were
made for known relevant differences, it is possible that the
groups differed in other important respects. In addition, the
present analysis lacked sufficient power to detect a small, but
perhaps clinically relevant, effect from beta-blockade. How-
ever, the present analysis had reasonable (.80%) power to
detect a prominent (35%) mortality reduction associated
with beta-blocker use (12,14). Finally, although the doses of
beta-blockers prescribed in randomized patients are lower
than what have been used in post-MI (1,2,29) and heart
failure trials (4,5), these doses are similar to what have been
reported in studies of similar patients with VT and VF
(6,32).
Conclusions. Although eligible, nonrandomized patients
who did not receive amiodarone or an ICD had a significant
survival benefit associated with beta-blockade, the role of
beta-blockers as monotherapy in patients with VT or VF is
limited because the ICD is more efficacious (33).
The AVID patients treated with amiodarone or an ICD
had no significant additional mortality reduction associated
with concurrent beta-blockade. However, because beta-
blockers confer additional benefits in the management of
patients with heart disease, it remains appropriate to pre-
scribe beta-blockers to patients with VF and symptomatic
VT in whom they are clinically indicated for other reasons.
Moreover, differences in the use of beta-blockers in ran-
domized AVID patients do not explain the increased
survival observed with ICD therapy.
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